Incyte Co. (NASDAQ:INCY) EVP Yao Wenqing sold 3,165 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $95.00, for a total value of $300,675.00. Following the sale, the executive vice president now owns 98,473 shares in the company, valued at approximately $9,354,935. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Yao Wenqing also recently made the following trade(s):
- On Monday, December 2nd, Yao Wenqing sold 16,835 shares of Incyte stock. The stock was sold at an average price of $95.00, for a total value of $1,599,325.00.
- On Friday, November 1st, Yao Wenqing sold 7,960 shares of Incyte stock. The shares were sold at an average price of $85.00, for a total value of $676,600.00.
- On Tuesday, October 29th, Yao Wenqing sold 2,040 shares of Incyte stock. The shares were sold at an average price of $85.00, for a total value of $173,400.00.
INCY traded down $0.37 during trading hours on Tuesday, hitting $94.10. The company’s stock had a trading volume of 1,436,703 shares, compared to its average volume of 1,272,574. The company has a 50-day simple moving average of $84.68 and a 200 day simple moving average of $81.54. The company has a current ratio of 5.02, a quick ratio of 5.01 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $20.28 billion, a PE ratio of 114.76, a PEG ratio of 1.37 and a beta of 1.00. Incyte Co. has a fifty-two week low of $57.00 and a fifty-two week high of $95.36.
Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.27. The company had revenue of $551.58 million during the quarter, compared to analyst estimates of $534.73 million. Incyte had a return on equity of 20.07% and a net margin of 19.21%. The firm’s quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.41 EPS. Research analysts expect that Incyte Co. will post 2.14 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of INCY. CSat Investment Advisory L.P. raised its stake in shares of Incyte by 180.5% in the 2nd quarter. CSat Investment Advisory L.P. now owns 676 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 435 shares in the last quarter. AQR Capital Management LLC raised its position in Incyte by 18.1% in the second quarter. AQR Capital Management LLC now owns 995,804 shares of the biopharmaceutical company’s stock worth $83,548,000 after acquiring an additional 152,553 shares in the last quarter. Morgan Stanley raised its position in Incyte by 5.3% in the second quarter. Morgan Stanley now owns 362,610 shares of the biopharmaceutical company’s stock worth $30,806,000 after acquiring an additional 18,193 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Incyte by 115,574.2% in the 2nd quarter. Bessemer Group Inc. now owns 564,490 shares of the biopharmaceutical company’s stock valued at $47,959,000 after acquiring an additional 564,002 shares during the last quarter. Finally, Amica Mutual Insurance Co. acquired a new stake in Incyte in the 2nd quarter valued at about $407,000. 91.10% of the stock is owned by institutional investors and hedge funds.
Several equities analysts recently issued reports on INCY shares. Morgan Stanley raised their price objective on Incyte from $82.00 to $87.00 and gave the stock an “equal weight” rating in a research note on Thursday, September 5th. ValuEngine lowered shares of Incyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 5th. Cowen reissued a “buy” rating on shares of Incyte in a report on Friday, September 27th. Mizuho restated a “buy” rating and issued a $98.00 price target on shares of Incyte in a research report on Wednesday, November 27th. Finally, BidaskClub raised shares of Incyte from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $93.05.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Featured Story: Forex
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.